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There has been an increase in the number of near-term and term infants reported with acute bilirubin encephalopathy, 
which has resulted in an increase in the number 
of readmissions of infants to hospitals. This can 
partially be attributed to shorter postpartum 
hospital stays, and limited post-natal follow-
up. To prevent kernicterus, clinicians need to 
understand the physiology of bilirubin production 
and excretion, and develop a systematic approach 
to the causes and management of neonatal icterus. 
This issue is highlighted here with specific relation 
to near-term and term newborns. 
Epidemiology 
Nearly all newborn infants have a total serum 
bilirubin (TSB) value greater than 1 mg/dL (17.1 
µmol/L), which is at the upper limit of normal for an 
adult. Most newborns appear clinically jaundiced. 
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 الريقان الوليدي يف الرضَّع الناضجني
 والقريبني من النضوج
نظرة عامة
ريحان علي، �ساكيل اأحمد، مقبول قادر، خليل اأحمد
ْلَبة العني عند االأطفال حديثي الوالدة ب�سبب تر�سب مادة البيلريوبني يف  امللخ�ص: الريقان الوليدي هو اللون االأ�سفر يف اجللد و/اأو �سُ
االأن�سجة. الريقان الف�سيولوجي يكون خفيفا عادة ب�سبب الِبيلريوبني الاَل ُمْقرَتِن  وي�سيب جميع املواليد اجلدد تقريبا. ترتفع م�ستويات 
الريقان الف�سيولوجي ما بني 5 و 6 ملغ / دي�سيلرت )103-86 مايكرو مول / لرت( عند 72 اإىل 96 �ساعة من العمر، وال تتجاوز 17 حتى 
18 ملغ / دي�سيلرت )308-291 مايكرو مول / لرت(. لكن م�ستويات البلريوبني قد ال ت�سل اإىل ذروتها حتى اليوم ال�سابع من العمر عند 
ن  ع الذين يولدون قبل االأوان )يف االأ�سبوع 37-35 من احلمل(. وتعترب م�ستويات الِبيلريوبني الاَل ُمْقرَتِ ع االآ�سيويني اأو عند الر�سّ الر�سّ
التي تكون اأعلى مما ُذكر حالة مر�سية وحتدث يف جمموعة متنوعة من الظروف. مت يف هذه الورقة مراجعة املظاهر ال�رضيرية وعالج 
الريقان الف�سيولوجي عند الر�سع االأ�سحاء، النا�سجني والقريبني من الن�سوج، وكذلك �سمية البيلريوبني والوقاية من الرَيَقان الَنَوِوّي، 
ومناق�سة االآلية املر�سية وامل�سببات املر�سية لهذا اال�سطراب على انفراد.
مفتاح الكلمات: الوليد، يرقان، ارتفاع البيلريوبني.
abstract: Neonatal jaundice is the yellowish discoloration of the skin and/or sclerae of newborn infants caused 
by tissue deposition of bilirubin. Physiological jaundice is mild, unconjugated (indirect-reacting) bilirubinaemia, 
and affects nearly all newborns.  Physiological jaundice levels typically peak at 5 to 6 mg/dL (86 to 103 µmol/L) 
at 72 to 96 hours of age, and do not exceed 17 to 18 mg/dL (291–308 µmol/L). Levels may not peak until seven 
days of age in Asian infants, or in infants born at 35 to 37 weeks’ gestation. Higher levels of unconjugated 
hyperbilirubinaemia are considered pathological and occur in a variety of conditions. The clinical features and 
management of unconjugated hyperbilirubinaemia in healthy near-term and term infants, as well as bilirubin 
toxicity and the prevention of kernicterus, are reviewed here. The pathogenesis and aetiology of this disorder are 
discussed separately. 
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Pathologic hyperbilirubinaemia occurs when the 
TSB exceeds the hour-specific 95th percentile 
using the published nomogram in Figure 1.1 The 
nomogram was developed for a racially diverse 
population in Philadelphia in which nearly 60% 
were breastfed. Infants were excluded if they had 
haemolytic conditions or required phototherapy 
before 60 hours to control rapidly rising TSB levels.
However, rates of hyperbilirubinaemia 
vary substantially between centres because of 
racial differences, haemolytic conditions, and 
breastfeeding practices. In a multinational study, 
the proportion of infants with TSB levels at or 
above the 95th percentile at 30 hours ranged from 
approximately 5% in Hong Kong and China, to 40% 
in Kobe, Japan.2
Clinical Features 
Risk factors for the development of jaundice in near-
term infants were obtained from clinical histories. 
They included gestational age of 35 to 37 weeks; 
polycythaemia; assisted deliveries through such 
methods as vacuum or forceps instrumentation; 
trauma during labour or delivery; maternal 
diabetes; Asian race; blood group incompatibility; 
poor breastfeeding practices, or a previous sibling 
with jaundice.3
Visual inspection of skin colour can be used to 
detect jaundice, but it is not a reliable method to 
assess the level of bilirubin or identify infants at 
risk for rapidly rising bilirubin levels, especially in 
those with dark skin.4 The examination should be 
performed with adequate ambient light. Pressing on 
the skin with a finger reduces local skin perfusion 
and may facilitate detection of jaundice.
Jaundice progresses in a cephalocaudal direction. 
The face and sclera typically appear icteric when 
bilirubin levels reach 6 to 8 mg/dL (103 to 137 
µmol/L), whereas the entire body, including palms 
and soles, appears jaundiced at values of 12 to 13 
mg/dL (205 to 222 µmol/L).5 TSB or transcutaneous 
bilirubin (TcB) levels should be measured in an 
infant with jaundice detected below the umbilicus. 
Physical examination may identify signs 
that suggest risk for pathological jaundice. They 























































1mg/dL = 17.1 micromol/L
Figure 1: Hour specific nomogram (adapted from Bhutani et al.1) 
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The TSB concentration is compared to an hour-
specific percentile-based nomogram. TSB levels 
in a term newborn typically peak at 5 to 6 mg/dL 
(86 to 103 µmol/L) at 72 to 96 hours of age, and do 
not exceed 17 to 18 mg/dL (291-308 µmol/L).1 The 
peak may not be reached until seven days of age in 
Asian infants, or in infants born at 35 to 37 weeks’ 
gestation.
Infants with hour-specific values that are greater 
than or equal to the 95th percentile are at increased 
risk for the development of clinically significant 
hyperbilirubinaemia, requiring intervention. In 
a racially diverse population with a 60% rate of 
breastfeeding, 95th percentile values for TSB were 
approximately 8, 10, 12, and 16 mg/dL (137, 171, 
205, and 274 µmol/L) at 24, 36, 48, and 72 hours, 
respectively.1
Infants who have TSB values greater than or 
equal to the 95th percentile, or who are suspected 
of having haemolytic disease, require subsequent 
measurement of TSB levels and further evaluation 
to determine the aetiology of their jaundice. Initial 
tests that should be obtained are blood type and 
direct anti-globulin tests, a complete blood count 
and smear, and a reticulocyte count. The mother’s 
blood type and antibody status usually are known 
from the prenatal history. If an infant is of Asian 
origin and the TSB concentration is ≥18 mg/dL 
(222 µmol/L), glucose-6-phosphate dehydrogenase 
(G6PD) should be measured.11 However, G6PD 
measurements are not universally available, and 
the results usually are not timely enough to affect 
clinical decisions.
end-tidal carbon monoxide 
End-tidal measurement of carbon monoxide (CO) 
corrected for ambient CO (ETCOc) provides a 
noninvasive assessment of bilirubin production 
because catabolism of heme results in equimolar 
quantities of bilirubin and CO.11–12 Elevated ETCOc 
values (>2.0 parts per million) can identify infants 
with increased bilirubin production (most often 
caused by haemolysis) who require additional 
evaluation or close monitoring. In one study, the 
ETCOc value at 30 hours of age exceeded the mean 
value (1.48 ppm) in 76% of hyperbilirubinaemic 
infants.12 
Kernicterus 
Bilirubin is a potential neurotoxin.6–7 Unconjugated 
bilirubin that is not bound to albumin (free 
bilirubin) can enter the brain and cause focal 
necrosis of the neurons and glia, resulting in 
bilirubin encephalopathy, which is also known 
as kernicterus. The regions most often affected 
include the basal ganglia and the brain stem nuclei 
for oculomotor and auditory function, accounting 
for the clinical features of this condition.8
Near-term and term infants are at risk for 
kernicterus when TSB concentrations exceed 25 
to 30 mg/dL (428 to 513 µmol/). However, the 
relationship between TSB and kernicterus is variable 
and influenced by other factors such as bilirubin 
affinity for albumin, which is reduced in premature 
and sick infants.9 Most unconjugated bilirubin is 
normally bound to albumin, resulting in low levels 
of free bilirubin. High TSB concentrations may 
exceed the capacity of albumin to bind bilirubin 
and lead to higher levels of free bilirubin, which 
may be neurotoxic. Although measurement of free 
bilirubin concentration would be useful to guide 
therapy, clinical testing is not universally available.
Drugs such as sulfisoxazole, moxalactam, and 
ceftriaxone can displace bilirubin from albumin and 
increase the risk of kernicterus. Acidosis increases 
movement of bilirubin into tissues and, thus, can 
contribute to the development of kernicterus.10
Kernicterus can occur in healthy term infants. 
However, infants at increased risk are those who 
are near term (35 to 37 weeks), breastfed, have 
haemolytic disease, and are discharged home 
before 48 hours. To minimise the risk of bilirubin 
encephalopathy, these infants require close 
surveillance because the peak TSB levels will be 
reached after discharge.7
Laboratory Evaluation
TSB and the direct-reacting serum bilirubin 
concentration are measured in infants with jaundice. 
If the direct-reacting bilirubin is greater than 1.5 to 
2.0 mg/dL (26 to 34 µmol/L), causes of cholestatic 
jaundice should be investigated. The following 
discussion applies to healthy term and near-term 
infants with hyperbilirubinaemia. Infants who 
appear ill or are premature require more extensive 
evaluation.
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transcutaneous bilirubin 
measurement 
Transcutaneous devices that use multi-wavelength 
spectral reflectance can be used to estimate TSB 
in order to avoid blood sampling. In contrast to 
older devices, this method is not affected by skin 
pigmentation.13 In one report of a racially and 
ethnically diverse group of 490 newborns, a close 
correlation was found between transcutaneous and 
TSB measurements.
Prevention of Severe 
Hyperbil irubinaemia
Infants with severe hyperbilirubinaemia are at risk 
for developing kernicterus, although only a small 
number will do so (see section on kernicterus 
above). Timely identification and treatment of 
infants with severe hyperbilirubinaemia will 
prevent most cases of kernicterus. Infants at risk 
require close surveillance and follow-up.14
Term and near-term infants should be evaluated 
for jaundice between 72 and 96 hours of age, the 
time at which TSB levels typically peak.1 However, 
many infants are discharged from the hospital prior 
to 48 hours of age; these infants should be examined 
for jaundice by a clinician within one to two days of 
discharge.
TSB levels are often higher in breastfed than in 
formula-fed infants. In addition, milk intake may 
be inadequate until lactation is well established, 
resulting in volume depletion and weight loss. 
Increased surveillance is needed for infants born 
at 35 to 37 weeks’ gestation because they are at 
increased risk for early difficulty with breastfeeding.
Counselling regarding jaundice and 
breastfeeding should be provided before discharge 
where the importance of frequent feedings should 
be emphasised. Lactation consultants and home 
visits by a nurse may be helpful. Until lactation 
is well-established in significantly jaundiced 
infants, it may be helpful to interrupt breast 
feeding briefly and supplement with formula for 
a short period (supplementation with water is not 
recommended).15
A root cause analysis of factors contributing 
to cases of kernicterus identified potentially 
correctable causes.15 These include: 1) discharge 
within 48 hours of birth with no follow-up within 
48 hours of discharge; 2) failure to measure the 
bilirubin concentrations in an infant with jaundice 
within 24 hours of birth; 3) failure to recognise 
risk factors for hyperbilirubinaemia; 4) lack of 
concern regarding the presence of jaundice; 5) 
delayed measurement of TSB in infants with severe 
jaundice; 6) delayed initiation of phototherapy 
in infants with elevated TSB levels, and 7) lack of 
response to parental concerns regarding jaundice, 
lethargy, or poor feeding.
prediction of severe 
hyperbilirubinaemia 
A percentile-based nomogram, such as that in 
Figure 1, can be used to predict the subsequent 
risk for severe hyperbilirubinaemia.1 In another 
report, the combined use of an hour-specific TSB 
measurement and ETCOc did not improve the 
predictive ability of an hour-specific TSB alone.16 
However, these clinical devices are not currently 
available. In this study, in contrast to the report 
on which the nomogram was based that used 
TSB alone, 4 of 620 infants with TSB levels in the 
low risk zone (<40th percentile) at 30 ± 6 hours 
subsequently developed TSB levels greater or equal 
to those in the 95th percentile. This finding supports 
the need for early follow-up of all infants regardless 
of their risk zone at discharge.
universal screening 
Universal screening of infants for TSB levels 
prior to discharge has been proposed to facilitate 
identification of infants at high risk for the 
development of severe hyperbilirubinaemia.2 
Limitations of this approach are the need for blood 
sampling and the cost of TSB measurement. Use of 
transcutaneous methods for screening may decrease 
the need for phlebotomy, and reduce costs.13,16  
An alternative approach is clinical assessment 
of jaundice before and within one to two days of 
discharge, and subsequent TSB measurement in 
jaundiced infants.
Treatments 
Phototherapy is the standard treatment for 
pathologic unconjugated hyperbilirubinaemia.17 
Rare cases of extremely high TSB levels (>25 mg/dl) 
require an exchange transfusion.
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can cause thermal injury. They should be placed at 
the manufacturer recommended distance from the 
patient. 
Fibre optic blankets generate little heat and can 
be placed close to the infant and provide higher 
irradiance than do fluorescent lights.19 However, 
blankets are small and rarely cover sufficient 
surface area to be effective when used alone in 
near-term and term infants. They can be used as 
an adjunct to overhead fluorescent or halogen 
lights. High intensity gallium nitride light emitting 
diodes (LEDs), such as neoblue, are as effective as 
conventional fluorescent light phototherapy.20
For intensive phototherapy (30 µW/cm2/nm) 
of infants with TSB levels greater than 25 mg/dL 
(428 µmol/L), a bank of special blue lights should be 
placed 10 to 12 cm from the infant’s body to expose 
the maximum surface area to light. Premature and 
hypothermic babies should be placed in an open 
crib or on a warmer. The area covered by the diaper 
should be minimised and the infant’s eyes should be 
shielded with a blindfold with care taken so that the 
blindfold does not cover the nose.
Temperature, time of exposure, irradiance (if 
possible), and the infant’s hydration status should 
all be monitored. Infants should continue oral 
feedings by breast or bottle. Intravenous hydration 
is needed only in cases of significant volume 
depletion. Phototherapy should be continuous, 
with interruptions only for feeding. If the TSB is at 
a near toxic level, fibre optic blanket exposure can 
continue during the feedings.
The following discussion applies to healthy term 
and near-term infants. Infants who appear ill or are 
premature require more aggressive intervention. 
For healthy term and near-term infants, we initiate 
phototherapy according to the 2004 practice and 
parameter recommendations of the American 
Academy of Pediatrics (AAP) on the management 
of hyperbilirubinaemia. Phototherapy is started if 
TSB levels are 15, 18, or 20 mg/dL (257, 308, and 
342 µmol/L) at 25 to 48, 49 to 72, or >72 hours after 
birth, respectively.2 These values exceed the 95th 
percentile for hour-specific TSB concentrations, 
predicting increased risk for developing severe 
hyperbilirubinaemia after discharge. For this reason, 
clinicians often initiate treatment for TSB levels 
that are 2 to 3 mg/dL (34–51 µmol/L) lower than 
the above values, especially for near term infants 
(35–37 weeks), or infants with other risk factors.2
phototherapy
Phototherapy consists of exposing the infant’s 
skin to blue-to-green light in wavelengths ranging 
from 400–520 nm. It is a safe and efficient method 
to reduce the toxicity of bilirubin and increase its 
elimination. Phototherapy detoxifies bilirubin by 
three mechanisms: structural isomerisation to 
lumirubin, photoisomerisation to a less toxic isomer, 
and photooxidation to polar small molecules. These 
processes are thought to occur in the blood vessels 
or interstitial spaces of the skin.
Phototherapy with blue light phototherapy 
converts bilirubin into lumirubin in a process of 
structural isomerisation that is not reversible.18 
Lumirubin, a more soluble substance than bilirubin, 
is excreted without conjugation into bile and urine. 
It is the principal mechanism by which phototherapy 
reduces the TSB concentration. Phototherapy 
with blue light phototherapy also converts the 
stable 4Z, 15Z bilirubin isomer to the 4Z, 15E 
isomer, which is more polar and less toxic than 
the common form. Like lumirubin, it is excreted 
into bile without conjugation. Unlike structural 
isomerisation to lumirubin, photoisomerisation 
is reversible, and some of the 4Z, 15E isomer in 
the bile is converted back into the stable 4Z, 15Z 
isomer. Photoisomerisation is the second important 
mechanism to increase bilirubin excretion. TSB 
photo oxidation reactions convert bilirubin to 
colourless, polar compounds that are excreted 
primarily in the urine. This mechanism accounts for 
a small proportion of bilirubin elimination.10
The dose of phototherapy, known as irradiance, 
times duration determines its efficacy. Irradiance 
depends upon the intensity of the blue light, its 
distance from the infant, and the surface area 
exposed. It usually is expressed for a certain 
wavelength band (spectral irradiance). Fluorescent 
blue light typically is used at a dose of approximately 
30 µW/cm2/nm of area exposed. Blue lights are 
more effective at reducing bilirubin but may 
interfere with the detection of cyanosis.17,18 The use 
of white daylight fluorescent lights/lamps is better 
than no phototherapy.
Fluorescent lights are placed 15 to 20 cm above 
the infant. We use light banks with eight alternating 
white and blue fluorescent bulbs. This combination 
increases the irradiance but lessens the eye strain 
for clinicians. Halogen white light lamps are hot and 
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Infants with clinical jaundice within the first 
24 hours of birth frequently have haemolysis. They 
require immediate evaluation and close surveillance 
to assess the need for phototherapy. In infants with 
other causes of increased bilirubin production, such 
as cephalohaematoma or extensive bruising, or in 
infants suspected of having conjugation disorders, 
we start phototherapy when the hour-specific TSB 
concentration is in a high intermediate risk zone 
(>75th percentile).
When TSB values are ≥20 mg/dL (342 µmol/L), 
the measurement should be repeated four to six 
hours after phototherapy is initiated to assess the 
response. For lower initial values, TSB should be 
measured after 24 hours and then once daily while 
phototherapy continues. However, measurement of 
serum bilirubin will also depend on the aetiology of 
the jaundice, rate of rise, etc., and may be indicated 
more often even when levels are not yet at 20 mg/
dL. A decrease in TSB level can be measured as 
soon as two hours after initiation of treatment. 
Intensive phototherapy should result in a decline of 
TSB of at least 1 to 2 mg/dL (17- 34 µmol/L) within 
four to six hours.2 
Our centre discontinues phototherapy when 
the hour-specific TSB level falls to a value less than 
the 95th percentile, or has decreased 4 to 5 mg/dL 
(68–86 µmol/L) when measured 18 to 24 hours 
later. Although the value following discontinuation 
is known as the rebound bilirubin, typically it is 
lower than the previous TSB during treatment. In 
one study of 161 infants with birth weights of more 
than 1800 grams, the rebound TSB was significantly 
lower 17 hours after termination of phototherapy 
(11.5 versus 12.2 mg/dL, 197 versus 209 µmol/L).21
Phototherapy is considered safe. Side effects 
include transient erythematous rashes, loose stools 
and hyperthermia. Increased insensible water loss 
caused by enhanced peripheral blood flow may lead 
to dehydration.
As an alternative to readmission to the hospital, 
phototherapy can be administered at home. Home 
phototherapy is less disruptive to the family and 
can be considered for healthy infants without 
haemolysis who are feeding well and can be closely 
followed.
exchange transfusion 
Exchange transfusion is used to remove bilirubin 
from the circulation when intensive phototherapy 
fails. It is especially useful for infants with increased 
bilirubin production from immune-mediated 
haemolysis because the circulating antibodies and 
the sensitised red blood cells also are removed.
An exchange transfusion is performed when 
severe hyperbilirubinaemia does not respond to 
intensive phototherapy. According to the AAP 
practice parameters, an exchange transfusion is 
indicated in healthy near-term and term infants 
when TSB levels are greater than or equal to 20 mg/
dL (342 µmol/L) at 24 to 48 hours of age, or are at 
or greater than 25 mg/dL (428 µmol/L) thereafter. 
Failure of intensive phototherapy occurs if TSB 
levels do not decrease by 1 to 2 mg/dL (17–34 
µmol/L) within four to six hours of initiation of 
phototherapy. An exchange transfusion also should 
be performed in infants with high TSB levels as per 
the nomogram, and in any infant with any signs of 
bilirubin neurotoxicity. 
Exchange transfusion is indicated in cases of 
haemolysis, especially immune-mediated, if the 
anaemia is severe and resulting in hydrops, or the 
TSB is rising rapidly and is expected to reach 25 
mg/dL (428 µmol/L) within 48 hours. Exchange 
transfusions will correct the anaemia without 
causing circulatory overload and remove maternal 
antibodies and sensitised erythrocytes. Less 
severely affected patients can be managed with 
intensive phototherapy to reduce TSB levels, and 
transfusions of packed red blood cells to correct the 
anaemia.
A double-volume exchange transfusion removes 
approximately twice the infant’s circulating blood 
volume (blood volume is approximately 80 to 90 
mL/kg), replacing it with appropriately cross-
matched fresh or reconstituted (from packed 
red blood cells and fresh frozen plasma) whole 
blood. The procedure involves placement of a 
central catheter and the subsequent removal and 
replacement of the maximum amount of blood that 
should be withdrawn at any one time (approximately 
5 ml per Kg body weight). Most of the bilirubin is 
extravascular; as a result, an exchange transfusion 
removes approximately 25% of the total body 
bilirubin.22 An infusion of albumin (1 g/kg) one 
to two hours before the procedure moves more 
extravascular bilirubin into the infant’s circulation, 
allowing removal of more bilirubin.23
After the procedure, TSB levels typically fall to 
approximately half of the pre-exchange value, and 
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metalloporphyrins
Synthetic metalloporphyrins, such as tin 
mesoporphyrin (SnMP), reduce bilirubin 
production by competitive inhibition of heme 
oxygenase.25 In one report, for example, term and 
near-term infants with G6PD deficiency given SnMP 
at approximately 27 hours of age had lower and 
earlier peak TSB values than did control infants with 
and without G6PD deficiency.11 No treated infant 
required phototherapy, compared to 31% and 15% 
in the controls with and without G6PD deficiency, 
respectively. However, metalloporphyrins are not 
available for clinical use.
Conclusion 
The following recommendations only apply to 
healthy term and near-term infants. Infants who 
appear ill, are premature, or have evidence of 
haemolysis require more intensive evaluation and 
management.
Infants should be assessed for jaundice at 24 
to 48 hours of age and prior to hospital discharge. 
Measurement of serum or transcutaneous bilirubin 
concentration is preferred. Alternatively, the 
infant can be assessed by visual inspection and a 
measurement of TSB levels should be obtained in 
those who appear jaundiced.
TSB values should be compared to an 
hour-specific nomogram to predict the risk of 
subsequent development of clinically significant 
hyperbilirubinaemia. Infants at high risk require 
increased surveillance.
Infants discharged within 48 hours of birth 
require a follow-up evaluation within 24 to 48 hours 
of discharge. Infants at high risk for the development 
of significant hyperbilirubinaemia should be 
evaluated within 24 hours of discharge. In addition, 
parents should also be told to return immediately 
if the infant becomes visibly more jaundiced or 
develops any sort of neurological symptom.
Lactation counselling should be provided for 
breastfeeding mothers. Near-term (35 to 37 weeks) 
infants are at greater risk of receiving inadequate 
fluid and nutrition, and require increased 
surveillance.
then increases to approximately two-thirds of that 
level as the extravascular and vascular bilirubin re-
equilibrate. A double volume exchange transfusion 
replaces approximately 85% of the infant’s red blood 
cells.
The risks of exchange transfusions result from 
the use of blood products and from the procedure 
itself. Possible complications include blood-borne 
infection, thrombocytopenia, coagulopathy, graft-
versus-host disease, necrotising enterocolitis, portal 
vein thrombosis, electrolyte abnormalities, cardiac 
arrhythmias, and sudden death.24
Most complications occur in sick infants and 
are rare in healthy infants. In a retrospective review 
of 15 years of experience at two academic medical 
centres, one of 81 healthy infants developed 
necrotising enterocolitis after exchange an 
transfusion, and none died.22
Pharmacological Agents  
Pharmacological agents, including intravenous 
immunoglobulin (IVIG), phenobarbital, and 
metalloporphyrins can be used to inhibit 
haemolysis, increase conjugation and excretion 
of bilirubin, or inhibit the formation of bilirubin. 
However, IVIG is currently used only to treat 
unconjugated hyperbilirubinaemia.
intravenous immunoglobulin 
Intravenous immunoglobulin IVIG (500 mg/kg per 
dose IV over two hours) may reduce the need for 
exchange transfusions in infants with haemolytic 
disease caused by Rh or ABO incompatibility.23 The 
mechanism is uncertain, but IVIG is thought to 
inhibit haemolysis by blocking antibody receptors 
on red blood cells.
phenobarbital
Phenobarbital increases the conjugation and 
excretion of bilirubin and decreases postnatal TSB 
levels when given to pregnant women or infants; 
however, prenatal administration of phenobarbital 
may adversely affect cognitive development and 
reproduction.24 As a result, phenobarbital is not 
used to treat indirect hyperbilirubinaemia. There 
are exceptional circumstances, like prolonged 
jaundice in Gilbert’s syndrome, where it might be 
useful.
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